Mojtaba Haji Mazdarani1, Milad Jafarikia2, Fahimeh Nemati3. 1. Department of Microbiology, Islamic Azad University of Varamin, Pishva, Iran. 2. Department of Genetic, Islamic Azad University of Varamin, Pishva, Iran. 3. Department of Biotechnology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
Abstract
INTRODUCTION: The aim of this study was to evaluate the expression of IDO-1 gene and cancerous grades of non-small cell lung cancer (NSCLC) and its subclasses among patients with lung cancer using real-time polymerase chain reaction (PCR). MATERIALS AND METHODS: A total of 35 clinical samples were collected from patients with NSCLC. To evaluate the IDO-1 gene after the extraction of RNA and complementary DNA (cDNA) synthesis using real-time PCR, the expression of the gene was investigated. The western blot analysis method was used for protein expression. RESULTS: The highest grade, IIIa grade included six patients (17.1%). Approximately 74% of adenocarcinoma cases were in T-categories of lung cancer and 25% of patients in IIIa grade. Patients in the IIA and IIB categories belong to the SCC subclass. Results showed that the expression of INDO 5.22 fold gene was more common in patients with lung cancer than NSCLC. Protein expression in western blot analysis in patients compared with normal 3.22 fold change increased. CONCLUSION: The evidence shows that IDO-1 is a key parameter that inhibits antitumor immune responses in humans. This study has added interesting data to the IDO community for analyzing the expression of cancerous human cancer cells and cancer tissue in humans. The results showed that IDO-1 not only participates in the process of escape from tumor immunity but can also contribute to the safety of the pretumor area. A wide variety of observed IDO-1 expression values among patients may present serious barriers to the clinical performance of anti- IDO strategies at present.
INTRODUCTION: The aim of this study was to evaluate the expression of IDO-1 gene and cancerous grades of non-small cell lung cancer (NSCLC) and its subclasses among patients with lung cancer using real-time polymerase chain reaction (PCR). MATERIALS AND METHODS: A total of 35 clinical samples were collected from patients with NSCLC. To evaluate the IDO-1 gene after the extraction of RNA and complementary DNA (cDNA) synthesis using real-time PCR, the expression of the gene was investigated. The western blot analysis method was used for protein expression. RESULTS: The highest grade, IIIa grade included six patients (17.1%). Approximately 74% of adenocarcinoma cases were in T-categories of lung cancer and 25% of patients in IIIa grade. Patients in the IIA and IIB categories belong to the SCC subclass. Results showed that the expression of INDO 5.22 fold gene was more common in patients with lung cancer than NSCLC. Protein expression in western blot analysis in patients compared with normal 3.22 fold change increased. CONCLUSION: The evidence shows that IDO-1 is a key parameter that inhibits antitumor immune responses in humans. This study has added interesting data to the IDO community for analyzing the expression of cancerous human cancer cells and cancer tissue in humans. The results showed that IDO-1 not only participates in the process of escape from tumor immunity but can also contribute to the safety of the pretumor area. A wide variety of observed IDO-1 expression values among patients may present serious barriers to the clinical performance of anti- IDO strategies at present.